PEG-Intron
information and resources from the National Cancer Institute
NCI Thesaurus | PEG-Intron
(Other name for: PEG-interferon alfa-2b)NCI Thesaurus | PEG-Intron
(Other name for: PEG-interferon alfa-2b)
|
|
|
|
news articles
Hepatitis C Market: Plenty Of Potential, But Little Progress 01 Apr 2006
Investor's Business Daily (subscription) ...protein that fights infection. Pegylated Interferon is sold as Pegasys by Roche and PEG-Intron by Schering-Plough. It reduces the ...
Biogen Idec Faces Long-Term Growth Challenges Mar 31, 2006
Forbes ...news - people ) will see European royalties phase out for cancer drug Rituxan, marketed by Roche, along with decreased royalties for Peg Intron and Angiomax ...
Novartis Licenses Hep C Drug Mar 29, 2006
Red Herring, Roche makes a $1.38-billion combination treatment for the disease called Pegasys/Copegus. Schering-Plough makes Peg-Intron/Rebetol, worth $1.1 billion a year. ...
SP rises on deal and analyst upgrades Mar 21, 2006
Pharma Times (subscription), ...has suffered since the demise of Rebetol (ribavirin) to generic competition and with increasing rivalry seen for its newer offering Peg-Intron (peg-interferon ...
Schering-Plough debt rating outlook raised to stable - S&P Mar 24, 2006
Forbes ...'The ratings on the company continue to reflect its diverse product portfolio, featuring major products Vytorin/Zetia, Remicade, PEG-Intron, and Clarinex, as ...
Enzon to Present at Cowen 26th Annual Health Care Conference Mar 3, 2006
Genetic Engineering News, In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and MACUGEN(R), marketed by OSI Pharmaceuticals ...
Enzon to Present at Cowen 26th Annual Health Care Conference Mar 3, 2006
Finanzen.net, In addition, Enzon alsoreceives royalties on sales of PEG-INTRON(R), marketed bySchering-Plough Corporation, and MACUGEN(R), marketed by OSIPharmaceuticals and ...
Higher doses of pegylated interferon or ribavirin improve ... Dec 8, 2005
Aidsmap, Participants were randomly assigned to receive pegylated interferon-alpha-2b (Viraferon-Peg or Peg-Intron) at doses of 0.5, 1.5, or 3mcg/kg/week, all with 800 ...
AASLD: Weight-Based Dosing of Rebetol Improves Outlook for HCV Nov 17, 2005
MedPage Today, The PEG-Intron dose was 1.5 mcg/kg/week. The combination of Rebetol and PEG-Intron has been established as the standard of care ...
Hepatitis C combination therapies in pill form move nearer Nov 18, 2005
Aidsmap, ...this open-label crossover study, all participants received 200 or 400mg SCH503034 monotherapy for seven days, pegylated interferon alpha-2b (Peg-Intron) 1.5 mcg ...
Livers Under Wrap: ASLD 2005 Nov 25, 2005
MedPage Today, In what researchers said was the largest therapeutic trial of HCV infection, 4.913 patients were randomized to PEG-Intron (peginterferon alfa-2b) once a week ...
Enzon Files sBLA for First-Line Use of ONCASPAR(R); FDA Accepts ... Dec 1, 2005
Genetic Engineering News, In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and MACUGEN(R), marketed by OSI Pharmaceuticals ...
Enzon Files sBLA for First-Line Use of ONCASPAR(R); FDA Accepts ... Dec 1, 2005
Finanzen.net, In addition, Enzon alsoreceives royalties on sales of PEG-INTRON(R), marketed bySchering-Plough Corporation, and MACUGEN(R), marketed by OSIPharmaceuticals and ...
Therapy May Aid Hepatitis Non-Responders, Early Study Results ... Dec 1, 2005
Hepatitis Neighborhood, The other, PEG-Intron (peginterferon alfa-2b) is manufactured by Schering-Plough Pharmaceuticals. Both are used in combination with ribavirin. ...
|
|
